Compare Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) (ITUB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) vs Repligen Corporation Common Stock — how do they compare? Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) trades at $9.45 (market cap $111.78B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) is far larger — about 9.9× Repligen Corporation Common Stock's market cap, and Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) pays a 1.77% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) for 3 Days and Repligen Corporation Common Stock for 0 Days on average.
| ITUB | RGEN | |
|---|---|---|
Market Cap | $111.78B | $11.31B |
Volume | 32,206,998 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $10.16 | $194.57 |
52-Week Low | $6.86 | $102.87 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $1.33T | $11.20B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITUB trades at $9.89, down 1.69% today, following recent profit-taking after reaching 52-week highs. The stock shows bullish technical momentum with strong moving average signals, though RSI indicates overbought conditions. Fundamentally, the bank maintains robust profitability with 27.65% net margin and 21.97% ROE, though recent quarters have seen earnings misses. The company recently received preliminary US bank charter approval, expanding its wealth management services for Latin American clients.
Outlook remains cautiously optimistic with analyst consensus at Buy (46%) and price target of $9.80. Key opportunities include US expansion and strong Brazilian market position, while risks include Brazil's high risk-free rate, competitive pressures, and earnings consistency concerns. The stock trades near fair value with P/E of 11.75 and P/B of 2.5.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)
Itaú Unibanco is a Brazilian financial services company providing banking, credit, insurance, and investment products. It serves individual, business, and corporate clients.
Read more on ITUB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
